To Observate Capecitabine As A Postoperation Adjuvant Chemotherapy On Patients With Colorectal Cancer

Objective:To evaluate the therapeutic effects and side effects of capecitabine as a postoperation adjuvant chemotherapy on patients with colorectal cancer.Methods:After retrospective analysis of all the colorectal cancer cases in DukesB and C grades with radical surgery during 2004-2005,the cases are divided into three groups:Xeloda group,5-FU/LV group and no chemotherapy group,based on their different approaches for chemotherapy.Xeloda Group:1500 mg bid per os,for 2 weeks with one week as an interval in a cycle,and 5FU/LV Group:LV200mg/d iv by drip and 5-FU375mg/m~2 iv by drip two hours later,lasting for 24 hours per day×1-5 days in every four weeks as a cycle.The study compared the toxic reactions and side effects in Xeloda Group and 5-FU/LV group. And we also compared the survival rates and metastasis-recurrence rate of the three groups based on the follow-up datas.Results:The survival rates of were 97%,89%and 83%, respectively,in Xeloda group;95%,83%and 73%,repectively,in 5-FU/LV group;and 88%,71%and 53%,respectively,in no chemotherapy group.The cumulative recurrence rates of one-year,two-year and three-year were 8%,25%and 34%,respectively, in Xeloda group;15%,22%and 35%,respectively,in 5-FU/LV group; 20%,45%and 59%,respectively,in no chemotherapy group.There was significant difference in statistics between any two in three Groups(P＜0.05).The hand-foot syndrome and skin pigmentation in Xeloda group were obvious,the rates of which were 48.6%and 48.6%in respective in Xeloda group,and 7.0%and 2.1%,respectively,in 5-FU/LV group.The statistical difference was significant(P＜0.05).Gastrointestinal reactions was the main toxic effect in 5-FU/LV group,in which nausea and vomiting were much obvious,the rates of which were 69.8%in 5-FU/LV group,and 27%in Xeloda group.The statistical difference was significant(P=0.001).Other side effects were no significant statistical differences.Conclusion:Xeloda has a significant therapeutic effect for patients with resectable colorectal cancer with light toxic reaction and can be tolerated by the patients.Xeloda is expected to become the preferred treatment for colorectal cancer adjuvant chemotherapy.